Pay in 4 interest-free payments of $7.10 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Treibel TA, Manisty C, Burton M, McKnight , Lambourne J, Augusto JB, et al
The SURMOUNT-4 trial further demonstrated that participants who discontinued tirzepatide experienced a 14.0% weight regain over a 52-week withdrawal phase, whereas continued therapy maintained an overall 25.3% reduction from baseline [117]
Evaluating Biometric Trend Drivers: How to reflect medical breakthroughs and other drivers in forward-looking assumptions explores the practicalities of maintaining an up-to-date view of emerging drivers such as AOMs and provides one framework for incorporating insured impacts into insured improvement bases
Tight junctions between intestinal epithelial cells restrict paracellular transport to molecules with radii well below those of therapeutic peptides, while transcellular transport favors lipophilic small molecules rather than hydrophilic macromolecules (Lundquist and Artursson, 2016)
US$ 28.00
US$ 20.08
US$ 21.38
US$ 22.64
US$ 23.47
US$ 20.96
US$ 23.95
US$ 21.50
US$ 26.11
